Concepedia

Pablo E. Pérgola

PE

83

Publications

8.4K

Citations

47

H-Index

1990

Active since

Affiliations

Renal Associates P. A.(Current)

The University of Texas Health Science Center at San Antonio

Stanford University

University of Alabama at Birmingham

Reata Pharmaceuticals (United States)

Pablo E. Pérgola is an author at Renal Associates P. A. specializing in medicine, nephrology, and chronic kidney disease.

ORCID

Top concepts

Publications per year

1990–2024

83

Publications

83

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

Pablo E. Pérgola, Philip Raskin, Robert D. Toto et al. · New England Journal of Medicine · 2011 · 868 citations · Full text

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres et al. · The Lancet · 2021 · 596 citations

, , +10

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

, , +7

Sodium Zirconium Cyclosilicate in Hyperkalemia

David Packham, Henrik Rasmussen, Philip T. Lavin et al. · New England Journal of Medicine · 2014 · 482 citations · Full text

Cutaneous Active Vasodilation in Humans Is Mediated by Cholinergic Nerve Cotransmission

Dean L. Kellogg, Pablo E. Pérgola, Kenneth L. Piest et al. · Circulation Research · 1995 · 363 citations

Rows per page

1–5 of 83